ArticleEye (London, England)2025
The safety and effectiveness of optometrist-delivered selective laser trabeculoplasty.
Article in Eye (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSelective laser trabeculoplasty (SLT) has been demonstrated to have an IOP-lowering effect similar to topical medication when used as a first-line treatment. Accordingly, demand for SLT has increased, requiring other allied health care professionals to be leveraged in the delivery of this service. Current evidence on the safety of optometrists performing SLT is sparse. The aim of this study was to assess the success rate of SLT delivered by optometrists in eyes with newly diagnosed ocular hypertension and/or glaucoma and individuals who had received SLT as a treatment escalation. The secondary aim of the study was to assess complications of SLT delivered by optometrists.
methodsThis was a retrospective study. Success rate was defined as ≥20% reduction in intraocular pressure (IOP), or the cessation of ≥1 class of anti-glaucoma medication in cases of treatment escalation. For the first-line treatment, success was quantified according to the disease diagnosis with specified levels of IOP reduction.
results880 eyes of 574 patients were included in the analysis. The success rate was 70.9% (244/344) in eyes with first-line SLT, whilst 65.3% (343/525) in the treatment escalation group. Overall, adverse events were identified in 2.2% of cases, including uveitis (0.92%), post-procedure transient IOP spike (0.45%), allergic reaction (0.23%), dry eye (0.23%), headache (0.11%), hyphaema (0.11%), and vitreo-macular traction 0.11%).
conclusionOptometrists delivered a safe and effective selective laser trabeculoplasty treatment with low rates of adverse events. Inter-optometrist differences in success rates were identified that require further elucidation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.